BERKELEY, CA --(Marketwired - November 30, 2016) - Dynavax Technologies Corporation (
- Abstract Name : SD-101, a Novel Class C CpG-Oligodeoxynucleotide Toll-like Receptor 9 Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial
- Abstract Number : 2974
- Date and Time : Sunday, December 4, 2016 from 6:00 p.m. EST to 8:00 p.m. EST
- Session Name : 623. Mantle Cell, Follicular and Other Indolent B-Cell Lymphoma - Clinical Studies: Poster II
- Location : San Diego Convention Center, Hall GH
- Note : Abstract will also be published online on December 1, 2016, in the supplemental volume of the journal Blood
About SD-101
SD-101 is Dynavax's proprietary, second-generation, Toll-like Receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its safety and activity.
For information about SD-101 trials that are currently recruiting patients, please visit www.clinicaltrials.gov .
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com .
Contact: Michael Ostrach Chief Financial Officer 510-665-7257 Email contact